Agouti-related protein (AGRP) is a naturally occurring antagonist of melanocortin action that is thought to play an important role in the hypotha
INTRODUCTION
Agouti-related protein (AGRP) is a recently discovered neuropeptide that has generated intense interest because a growing body of evidence indicates it has a major role in the regulation of mammalian feeding behavior (1, 2). AGRP was identified by virtue of its sequence similarity to the product of the Agouti coat color gene, a paracrine signaling molecule normally expressed in skin whose transient expression during hair growth leads to the barring of coat fur in rodents (e.g. dark hair with a subapical yellow band) (3) .
Ubiquitous expression of Agouti, which occurs in mice that carry mutations in the 5Ј-flanking region of the Agouti gene, gives rise to pleiotropic effects including a yellow coat, obesity, insulin resistance, increased body length, and premature infertility (4) . The recent identification of AGRP indicates that the obesity and diabetes caused by ectopic Agouti expression are likely explained by its ability to mimic AGRP, since ubiquitous expression of AGRP in transgenic mice causes an increased weight gain and body length phenotype identical to that produced by ubiquitous expression of Agouti (2) . Structurally, however, the similarity between Agouti and AGRP is confined almost entirely to their 40-residue carboxyl termini where a total of 20 residues, including 10 cysteine residues, are identical (Fig. 1) .
Both Agouti and AGRP have been shown to antagonize the action of melanocortin peptides such as ␣-MSH and ACTH at specific melanocortin receptor subtypes. Agouti potently antagonizes the action of melanocortins at the melanocyte melanocortin recep-tor (MC1R), adrenocortical ACTH receptor (MC2R), and the MC4R (5, 6) . In contrast, we recently demonstrated that AGRP primarily antagonizes the MC3R and MC4R (2) , each of which is expressed in areas of the hypothalamus implicated in feeding behavior (7, 8) . Some or all of the growth and weight gain phenotypes caused by Agouti or AGRP are likely mediated via the MC4R, since mice carrying an MC4R knockout mutation display obesity and metabolic abnormalities similar to those caused by ubiquitous expression of Agouti or AGRP (2, 9) .
Several explanations have been proposed to explain the mechanism of Agouti or AGRP action, including simple competitive antagonism (10) , inverse agonism (11) , or activation of an effector other than adenylate cyclase (12) . Distinguishing among these alternatives has been complicated, in part, by the absence of direct assays for Agouti or AGRP binding, since a hallmark of competitive antagonism is the ability of agonist to displace labeled antagonist. We have recently demonstrated that an epitope-tagged form of Agouti protein interacts directly with the MC1R in an overlay experiment, but these assays are not quantitative and so do not allow a comparison among different receptors or antagonists (13) .
Our previous studies were carried out with preparations of recombinant AGRP that were partially purified and heterogeneous in length. In contrast to recombinant techniques, chemical protein synthesis can be used to make a homogeneous preparation of defined molecular structure that can be chemically labeled and derivatized and that can serve as a substrate for structure-function analyses. Here we describe the application of two novel chemically synthesized AGRP variants to studies directed at understanding the mechanism of AGRP action. The first, AGRP(87-132), is a 46-residue peptide containing five disulfide bonds formed by folding the C-terminal portion of human AGRP. We demonstrate that radioiodinated AGRP(87-132) can be used as a high-affinity tracer to directly quantitate cell surface AGRP binding. The second variant, mouse [Leu127Pro]AGRP, is a 111-amino acid AGRP molecule (mature AGRP minus its 20-amino acid signal sequence) that was made by joining the N-terminal residues 21-85 of mouse AGRP to human AGRP(87-132) by native chemical ligation (14) . In these studies we address three important issues: 1) the bioactivity of the synthetic AGRPs; 2) the binding properties of AGRP; and 3) the demonstration that AGRP(87-132) maintains the activity of full-length AGRP.
RESULTS

Effect of Mouse [Leu127Pro]AGRP and Human AGRP(87-132) on ␣-MSH-Stimulated cAMP Generation in Cell Lines Transfected with Melanocortin Receptors
To help verify the biological activity of the chemically synthesized proteins, we examined the ability of the proteins to inhibit ␣-MSH-stimulated cAMP generation. We have shown previously that partially purified recombinant human AGRP is a potent antagonist of the hMC3R and hMC4R, but has little or no effect on the hMC1R, hMC2R, or hMC5R. Figure 2 , A-E, demonstrates that chemically synthesized mouse [Leu127Pro]AGRP potently inhibits the action of ␣-MSH at the hMC3R and hMC4R. With increasing concentrations of mouse [Leu127Pro]AGRP, a progressive rightward shift of the ␣-MSH dose-response curves is observed. Mouse [Leu127Pro]AGRP was completely devoid of activity at the hMC1R and hMC2R. However, at higher concentrations, mouse [Leu127Pro]AGRP had a modest inhibitory effect on ␣-MSH action at the hMC5R. Schild analysis performed by plotting a linear regression of the log concentration of AGRP (x-axis) and log (DR-1) (y-axis) revealed a slope of 0.94 and 0.96 for mouse [Leu127Pro]AGRP at the hMC3R and hMC4R, respectively (Fig. 2, D ␣-MSH at the hMC3R and hMC4R of 3.3 Ϯ 0.28 nM and 2.6 Ϯ 0.21 nM, respectively. We also examined the effect of recombinant human AGRP Form A ϩ B on ␣-MSH-stimulated cAMP generation at the hMC4R (Fig. 2F) . Although the dose-response curves for recombinant human AGRP Form A ϩ B were not parallel, a linear regression of the data revealed a slope of 0.94 and K i of 1.2 Ϯ 0.17 nM (Fig. 2F, inset) . In contrast to chemically synthesized mouse [Leu127Pro]AGRP, the E max of ␣-MSH in the presence of recombinant human AGRP Form A ϩ B was about 10% below that observed in the absence of this antagonist. Neither chemically synthesized nor recombinant AGRP had an effect on cAMP accumulation when applied to cells in the absence of agonist. Previous biochemical studies of Agouti protein have been complicated by the lack of a radiolabeled derivative. In contrast, AGRP has two tyrosine residues, both of which are present in its carboxyl-terminal sequence. We were therefore able to take advantage of the purity of chemically synthesized human AGRP(87-132) to use standard oxidative chemistries to generate a radiolabeled molecule that exhibited specific binding to hMCR-expressing cells. In initial autoradiographic experiments using slides coated with photoemulsion, we asked whether tracer amounts of [ (Fig. 4 and data not shown) . The intensity of the binding studies is consistent with the rank order of AGRP inhibition noted in our functional studies (hMC4R ϭ hMC3R Ͼ hMC5R).
As a quantitative measure of binding, we examined the ability of unlabeled AGRP(87-132) to displace [ 125 I]AGRP(87-132) from the hMC3R, hMC4R, and hMC5R-expressing cells (Fig. 3C) . Notably, the displacement curves of [ 125 I]AGRP(87-132) from the hMC3R and hMC4R are overlapping, which is consistent with our previous functional and photoemulsion studies and indicate that AGRP(87-132) is essentially 
DISCUSSION
The identification of AGRP has added additional complexity to our attempts to understand weight homeostasis. Recent pharmacological and anatomical data have further strengthened the link between melanocortins and weight control and indicate that melanocortins act downstream of the fat hormone leptin (16) (17) (18) (19) . Levels of AGRP mRNA exhibit up to 10-fold alterations in different obesity models (1, 2) and, therefore, as a naturally occurring orexigenic agent that antagonizes melanocortins, AGRP may represent a unique target for antiobesity drug development.
While our previous studies of the action of baculovirus-produced AGRP allowed us to determine some aspects of this regulatory protein's action, our inability to produce highly purified product led us to consider an alternative approach. Chemical protein synthesis uses native chemical ligation of unprotected synthetic peptide segments in aqueous solution, followed by folding/disulfide formation to give the functional protein molecule (14) . Our present experiments demonstrate that the techniques of chemical protein synthesis can be used to rapidly produce highly purified, biologically active AGRP molecules in amounts of tens of milligrams in a convenient and straightforward fashion. In the present correspondence we capitalized on the use of these synthetic techniques to build upon our previous observations of AGRP. The availability of highly purified AGRP protein variants allowed us not only to readily develop an AGRP radioligand with which the site of AGRP action could be explored, but also enabled us to perform more detailed pharmacological analysis of this molecule.
Both chemically synthesized mouse [Leu127Pro] AGRP and AGRP(87-132) have similar inhibitory potency and efficacy as baculovirus-produced human AGRP Form A ϩ B. In cAMP assays [Leu127Pro] AGRP, AGRP(87-132), and recombinant human AGRP Form A ϩ B are essentially equipotent at inhibiting the hMC4R. Both chemically synthesized variant AGRP molecules were also found to display a similar nanomolar range of activity as previously observed for human recombinant Form A ϩ B at the hMC3R (2). Like recombinant human Form A ϩ B, both chemically synthesized AGRP variants had only minimal activity at the hMC5R, and neither displayed any inhibitory activity at the hMC1R or the hMC2R. AGRP(87-132) was only slightly more potent than either longer synthetic or recombinant forms of AGRP in displacing [ (Fig. 3) . Typical displacement curves appear to indicate that the iodination process did not alter the biological activity of AGRP(87-132). The finding that the displacement of [ 125 I]AGRP(87-132) from the hMC5R was shifted to the right is consistent with the decreased potency of AGRP at this receptor subtype observed in cAMP assays.
A persistent controversy that has existed regarding the action of Agouti protein is whether it has effects independent of its antagonism of ␣-MSH (11-13). Much of this speculation is based on the sequence similarity between agouti protein, and cone snail (conotoxins) and spider (plectoxins) toxins. These toxins, which affect calcium channels, contain a cysteinerich motif that can be closely aligned against 10 cysteine residues present in the C terminus of both Agouti and AGRP (Fig. 1) . While some of the effects of Agouti in the absence of ␣-MSH may be explained by its ability to act as inverse agonist, it has been suggested that a separate agouti receptor may exist (20, 21) . This controversy has been approached by examining the action of Agouti on melanoma cell lines lacking the MC1R (13) . More recently, epitope-tagged Agouti has been used (22 The competitive pattern of AGRP inhibition of melanocortins binding to the MC3R and MC4R observed in the present studies does not necessarily imply that AGRP and melanocortin agonist occupy the same site on the receptor. It is possible that the two ligands simply influence each other's binding through an allosteric mechanism. In fact, there is no significant sequence similarity between melanocortins and AGRP, although this does not exclude some similarity on the basis of three-dimensional structure. Future receptor mutagenesis studies using our novel radioligand ]MSH-MSH from hMC4R-expressing cells, the antagonists were equipotent in their ability to inhibit ␣-MSH-induced cAMP accumulation mediated by the hMC4R. Regardless of the reasons for this apparent difference, these results indicate that the structural determinants for both MCR binding and melanocortin antagonism are located within the cysteine-rich C-terminal domain. Furthermore, AGRP(87-132) retains the pattern of melanocortin receptor selectivity displayed by the fulllength molecule. Further truncation and other manipulations of human AGRP(87-132) will help identify its minimally active form, and modification of residues within this fragment should provide insight into the determinants of receptor subtype selectivity.
In summary, these studies demonstrate the ability to chemically synthesize biologically active AGRP variants. These studies also demonstrate that AGRP(87-132), a variant lacking the N terminus of AGRP and consisting of only the C-terminal cysteine-rich AGRP module, retains the biological activity of full-length AGRP. Finally, these studies describe the AGRP radioligand, [ 
MATERIALS AND METHODS
Mouse [Leu127Pro]AGRP and AGRP(87-132) Synthesis
Peptides were synthesized by Boc chemistry using manual stepwise solid-phase peptide synthesis as previously de-scribed (23) . The 46-amino acid polypeptide corresponding to the C-terminal module, human AGRP(87-132), was assembled on Thr-OCH 2 -Pam-resin (Perkin-Elmer Applied Biosystems, Foster City, CA). The N-terminal basic segment, mouse AGRP 21-85, was assembled on a thioester resin. Peptides were cleaved from the resin with hydrogen fluoride containing 5-10% p-cresol (Fluka, Buchs, Switzerland) for 1 h at 0 C, lyophilized, and then purified using reversed phase HPLC on C4 columns (Vydac, Murrieta, CA) with water (0.1% trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic acid) gradients. The molecular weights of these peptides were confirmed by electrospray ionization mass spectrometry (Perkin-Elmer SCIEX, Foster City, CA). To generate the fulllength construct, purified mouse AGRP (21-85) Baculovirus-produced recombinant human AGRP Form A ϩ B was produced and partially purified as previously described (2, 24) . Form A ϩ B refers to nonhomogeneous fractions of recombinant AGRP that run closely together on Western blot (2) . Form A consists of mature AGRP minus its signal sequence of 20 amino acids, and Form B contains several fragments cleaved after residues 46, 48, or 50. cAMP Assays cAMP generation was measured using a competitive binding assay kit (TRK 432, Amersham, Arlington Heights, IL) according to a standardized protocol (6) . Heterologous cell lines stably expressing the human (h) melanocortin receptors that have been previously described were used in these assays (6) . For assays, culture media were removed and cells were incubated with 0.5 ml Earle's balanced salt solution that contained AGRP and melanocortin agonist for 30 min at 37 C in the presence of 10 Ϫ3 M isobutylmethylxanthine. The reaction was stopped by adding ice-cold 100% ethanol (500 l/well). The cells in each well were scraped and transferred to a 1.5-ml tube and centrifuged for 10 min at 1900 ϫ g, and the supernatant was evaporated in a 55 C water bath with prepurified nitrogen gas. cAMP content was measured according to instructions accompanying the assay kit. ␣-MSH and human ACTH 1-39 were obtained from Peninsula Laboratories, Inc. (Belmont, CA). Each experiment was performed a minimum of three times with duplicate wells. The mean value of the dose-response data were fit to a sigmoid curve with a variable slope factor using the nonlinear squares regression in Graphpad Prism (Graphpad Software, San Diego, CA). EC 50 values determined from these fits were used for plotting Schild analysis linear regressions. pA 2 values were derived from the y ϭ 0 intercept of the Schild plot of the log of dose ratio minus one (log DR-1) as previously described (6) . K i values were determined as the negative log of the pA 2 . All statistical analyses represent the mean of the data Ϯ SE. (26) .
Radioiodination
125 I-labeled Na (0.5 mCi) (Amersham) was added to 20 g of either NDP-MSH or AGRP(87-132) in 5 l of 50 mM sodium phosphate buffer (pH 7.4). Ten microliters of a 2.4 mg/ml solution of chloramine T (Sigma Chemical Co., St. Louis, MO) in 50 mM sodium phosphate (pH 7.4) were added for 15 sec, and the reaction was stopped with 50 l of a 4.8 mg/ml solution of sodium metabisulfite (Sigma). The reaction mixture was then diluted in 800 l of 50 mM ammonium acetate (pH 5.8) and purified by reverse phase chromatography. BSA (100 l of a 2% solution) was added to all fractions containing radioactivity.
Binding Experiments
After removal of media the cells were washed twice with MEM and then preincubated with AGRP in 0.5 ml MEM (Life Technologies, Gaithersburg, MD) containing 0.2% BSA for 30 min before incubation with radioligand. Binding experiments were performed using conditions previously described (6) . I-AGRP(87-132) (ϳ55 fmol) were used. Binding reactions were terminated by removing the media and washing the cells twice with MEM containing 0.2% BSA. The cells were lysed with 0.1 N NaOH 1% Triton X-100, and the radioactivity in the lysate was quantified in an analytical ␥-counter. Nonspecific binding was determined by measuring the amount of 125 I-label remaining bound in the presence of 10 Ϫ5 M unlabeled ligand, and specific binding was calculated by subtracting nonspecifically bound radioactivity from total bound radioactivity. Typically, total binding of [ 125 I]AGRP(87-132) was about 13.5 Ϯ 1.3 ϫ 10 4 cpm, and nonspecific binding was 3.0 Ϯ 0.4 ϫ 10 3 cpm. For photoemulsion studies, the binding assays were performed directly on a chambered microscope slides (SlideFlask, NUNC, Roskilde, Denmark). Approximately 10 5 cells were placed on each slide and allowed to grow for 12 h. After binding experiments were performed, slides were fixed with gluteraldehyde and dried. Slides were then dipped in Kodak NTB2 photoemulsion (Eastman Kodak Co., New Haven, CT) and exposed for 3 days before being developed, examined, and photographed using a Leica DMRB microscope (Leica, Inc., Deerfield, IL).
